Cargando…

Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.

In this study we have investigated the role of thrombospondin (TSP) as a possible ligand playing a key role in human M3Da. melanoma cell interaction with platelets and in tumour growth. TSP is secreted (80 +/- 6 ng TSP 10(-6) cells) and bound to the surface of M3Da. cells via receptors different fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Boukerche, H., Berthier-Vergnes, O., Tabone, E., Bailly, M., Doré, J. F., McGregor, J. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034115/
https://www.ncbi.nlm.nih.gov/pubmed/7599038
_version_ 1782136985849167872
author Boukerche, H.
Berthier-Vergnes, O.
Tabone, E.
Bailly, M.
Doré, J. F.
McGregor, J. L.
author_facet Boukerche, H.
Berthier-Vergnes, O.
Tabone, E.
Bailly, M.
Doré, J. F.
McGregor, J. L.
author_sort Boukerche, H.
collection PubMed
description In this study we have investigated the role of thrombospondin (TSP) as a possible ligand playing a key role in human M3Da. melanoma cell interaction with platelets and in tumour growth. TSP is secreted (80 +/- 6 ng TSP 10(-6) cells) and bound to the surface of M3Da. cells via receptors different from CD36, as shown by biosynthetic labelling and immunofluorescence studies. The levels of TSP binding to M3Da. cells evaluated by binding studies, using an anti-TSP monoclonal antibody (MAb) (LYP8), shows 367,000 +/- 58,000 (mean +/- s.d.) LYP8 binding sites per cell with a dissociation constant (Kd) of 67 nM. TSP binding to M3Da. cells shows 400,000 +/- 50,000 TSP binding sites per cell with a Kd of 10 nM. The capacity of anti-TSP MAb (LYP8) to inhibit M3Da.-platelet interactions was followed on an aggregometer and evaluated by electron microscopy studies. The biological role of TSP binding to M3Da. cells was investigated by implanting subcutaneously the M3Da. cell line in nude mice and following the size and time of in vivo tumour growth. Reducing the availability or the functional level of TSP by using an anti-TSP MAb (LYP8) resulted in a significant decrease in platelet aggregates interacting with M3Da. melanoma cells. Using an enzyme-linked immunosorbent assay, purified alpha nu beta 3 was shown to bind TSP. Moreover, LYP8-coated M3Da. cells showed a reduced capacity to form tumours in vivo. M3Da. cells were observed to attach and spread on human platelet TSP-coated plastic wells. This attachment by M3Da. cells was inhibited in a similar way by LYP8 and an anti-alpha nu beta 3 MAb (LYP18). The results obtained in this study show that TSP secreted and bound to the surface of a human melanoma cell line (M3Da.) acts as a link between aggregated platelets and the M3Da. cell surface. Moreover, these results shows that TSP can modulate tumour growth in vivo. Reagents such as MAbs directed against TSP and peptides derived from TSP could not only be used as a new therapeutic approach in the control of tumour metastasis of melanoma, but may also contribute to elucidation of the role of TSP in cancer biology. IMAGES:
format Text
id pubmed-2034115
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20341152009-09-10 Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo. Boukerche, H. Berthier-Vergnes, O. Tabone, E. Bailly, M. Doré, J. F. McGregor, J. L. Br J Cancer Research Article In this study we have investigated the role of thrombospondin (TSP) as a possible ligand playing a key role in human M3Da. melanoma cell interaction with platelets and in tumour growth. TSP is secreted (80 +/- 6 ng TSP 10(-6) cells) and bound to the surface of M3Da. cells via receptors different from CD36, as shown by biosynthetic labelling and immunofluorescence studies. The levels of TSP binding to M3Da. cells evaluated by binding studies, using an anti-TSP monoclonal antibody (MAb) (LYP8), shows 367,000 +/- 58,000 (mean +/- s.d.) LYP8 binding sites per cell with a dissociation constant (Kd) of 67 nM. TSP binding to M3Da. cells shows 400,000 +/- 50,000 TSP binding sites per cell with a Kd of 10 nM. The capacity of anti-TSP MAb (LYP8) to inhibit M3Da.-platelet interactions was followed on an aggregometer and evaluated by electron microscopy studies. The biological role of TSP binding to M3Da. cells was investigated by implanting subcutaneously the M3Da. cell line in nude mice and following the size and time of in vivo tumour growth. Reducing the availability or the functional level of TSP by using an anti-TSP MAb (LYP8) resulted in a significant decrease in platelet aggregates interacting with M3Da. melanoma cells. Using an enzyme-linked immunosorbent assay, purified alpha nu beta 3 was shown to bind TSP. Moreover, LYP8-coated M3Da. cells showed a reduced capacity to form tumours in vivo. M3Da. cells were observed to attach and spread on human platelet TSP-coated plastic wells. This attachment by M3Da. cells was inhibited in a similar way by LYP8 and an anti-alpha nu beta 3 MAb (LYP18). The results obtained in this study show that TSP secreted and bound to the surface of a human melanoma cell line (M3Da.) acts as a link between aggregated platelets and the M3Da. cell surface. Moreover, these results shows that TSP can modulate tumour growth in vivo. Reagents such as MAbs directed against TSP and peptides derived from TSP could not only be used as a new therapeutic approach in the control of tumour metastasis of melanoma, but may also contribute to elucidation of the role of TSP in cancer biology. IMAGES: Nature Publishing Group 1995-07 /pmc/articles/PMC2034115/ /pubmed/7599038 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Boukerche, H.
Berthier-Vergnes, O.
Tabone, E.
Bailly, M.
Doré, J. F.
McGregor, J. L.
Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.
title Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.
title_full Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.
title_fullStr Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.
title_full_unstemmed Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.
title_short Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.
title_sort thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034115/
https://www.ncbi.nlm.nih.gov/pubmed/7599038
work_keys_str_mv AT boukercheh thrombospondinmodulatesmelanomaplateletinteractionsandmelanomatumourcellgrowthinvivo
AT berthiervergneso thrombospondinmodulatesmelanomaplateletinteractionsandmelanomatumourcellgrowthinvivo
AT tabonee thrombospondinmodulatesmelanomaplateletinteractionsandmelanomatumourcellgrowthinvivo
AT baillym thrombospondinmodulatesmelanomaplateletinteractionsandmelanomatumourcellgrowthinvivo
AT dorejf thrombospondinmodulatesmelanomaplateletinteractionsandmelanomatumourcellgrowthinvivo
AT mcgregorjl thrombospondinmodulatesmelanomaplateletinteractionsandmelanomatumourcellgrowthinvivo